NEW YORK, Feb. 13 - Hyseq on Wednesday said that it will license technology from Genetastix to generate fully human monoclonal antibodies against one of its antigens.

Terms of their agreement call for Hyseq to give Genetastix an upfront payment as well as research and development payments to use its HuMYTech technology.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

American scientists find themselves once again warning the Trump administration not to dismiss science, the New Yorker report.

A new study suggests CRISPR could be used to save coral reefs from dying off, Forbes reports.

Researchers have found that the i-motif shape of DNA previously observed in the lab also exists in human cells, and that it may serve a purpose.

In PNAS this week: a genomic, transcriptomic, and metabolomic analysis of the tea plant, Arabidopsis thaliana's adaptations to specific local environments, and more.